Beginning May 2018, BC is transitioning to pentavalent rotavirus vaccine (RotaTeq®) in the publicly funded rotavirus immunization program.
For more information see
Updates to the Rotavirus Immunization Program: Product Change Q&A and the letter to health care providers,
Rotavirus Imunization Program: Transitioning to pentavalent rotavirus vaccine (RV5, RotaTeq®).
The rotavirus vaccine helps protect against gastroenteritis (diarrhea and vomiting) caused by rotavirus. The vaccine also helps prevent the spread of rotavirus infection to others. It does not protect against diarrhea and vomiting caused by other viruses.
The vaccine has been shown to provide very good protection against rotavirus infection and prevents almost all severe cases of rotavirus gastroenteritis including hospitalization.
The rotavirus vaccine is a live attenuated vaccine and is part of the routine immunization schedule. When the rotavirus immunization program was first introduced in BC in 2012, Rotarix® was the vaccine product used and was given orally at 2 and 4 months of age.
Beginning May 2018, BC will begin transitioning to the RotaTeq® vaccine product. RotaTeq® vaccine is given orally at 2, 4 and 6 months of age. The maximum age for the first dose of rotavirus vaccine is 20 weeks less 1 day and the vaccine series should be completed by 8 months of age.
For more information regarding eligibility, guidelines for use and contraindications, please refer to the BC Immunization Manual, Part 4 - Biological Products, Rotavirus Vaccines,
Canadian Immunization Guide:
National Advisory Committe on Immunization: